Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about recent article by Niekbachsh Mohammadnia et al., published in JAMA Cardiology, adding:
“Does elevated Lp(a) always mean the same cardiovascular risk?
This new JAMA Cardiology study suggests the answer is no.
Among more than 43,000 individuals followed for over 13 years, IL-6 emerged as the only inflammatory biomarker that significantly modified the association between elevated Lp(a) and incident coronary artery disease.
Patients with both high Lp(a) and high IL-6 had substantially greater coronary risk, whereas elevated Lp(a) alone carried much less excess risk when IL-6 levels were low.
Interestingly, this interaction was not observed for aortic stenosis, suggesting different biological mechanisms despite Lp(a) being a shared risk factor.
These findings reinforce the concept that cardiovascular prevention may increasingly rely on combining lipid biology with inflammatory profiling, potentially helping identify those who could derive the greatest benefit from emerging Lp(a)-lowering and anti-inflammatory therapies.
What do you think will become the next essential biomarker in preventive cardiology: IL-6, hsCRP, or something else?”
Title: Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis
Authors: Niekbachsh Mohammadnia, Linke Li, MSc, Daniel Ezzat, BSc, Zhi Yu, MB, PhD, Vineet K. Raghu, PhD, Jennifer L. Halford, Niels P. Riksen, PhD, Pradeep Natarajan, MMSc, Jan H. Cornel, PhD, Michael C. Honigberg, MPP, Saloua El Messaoudi, PhD
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 4, 2026, 15:41Emmanuel J. Favaloro: New Research Highlights Benchmarks for Low Molecular Weight Heparin Monitoring
-
Jul 4, 2026, 15:38Roshni Kulkarni: Maternal Mortality In Bleeding Disorders
-
Jul 4, 2026, 15:20Bruno Pougault: Heparin Monitoring Remains One of the Most Challenging Areas in Laboratory Hemostasis
-
Jul 4, 2026, 15:12Rethinking Stroke Prevention – New Frontiers in Minimizing Bleeding Concerns – ISTH
-
Jul 4, 2026, 14:40Liver Cirrhosis and Portal Vein Thrombosis: Understanding a Critical Complication
-
Jul 4, 2026, 14:40Debra Bellon: A Milestone for Global Rare Disease Advocacy in Nairobi
-
Jul 4, 2026, 14:11Erica Wood: Next Webinar from the Optimal Centre of Research Excellence on Improving Immunoglobulin Use
-
Jul 4, 2026, 14:07Ariela Marshall: Optimizing Inpatient Hematology Consult Services Through Best Practices And Strategy
-
Jul 4, 2026, 13:53Azusa Nagao: Why Is von Willebrand Disease Still Being Missed in Japan?